Drupal.behaviors.print = function(context) {window.print();window.close();}>
Alnylam Takes License to Fundamental Gene-Silencing Patent
May 24, 2012
Alnylam Takes License to Fundamental Gene-Silencing Patent
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Dicerna Licenses Gene Silencing IP from Plant Bioscience Limited
April 11, 2013 / Gene Silencing News
Tekmira on Track to Move Cancer Drug into Phase II, Name New Clinical Candidate in ‘13
May 16, 2013 / Gene Silencing News
IP Update: Recent Patents, Patent Applications Awarded to Alnylam, Merck, BASF, and More
April 18, 2013 / Gene Silencing News
Tekmira to Present Cancer Drug Data at AACR, Aims for Phase II by Year-End
March 28, 2013 / Gene Silencing News
Alnylam Starts Phase I Trial of Subcutaneous ATTR Drug
March 21, 2013 / Gene Silencing News